What did @abbey.aultman actually say?
Abbey ruptured her Achilles in February, had surgery in March, and at roughly 11 weeks post-op started injecting a BPC-157 and TB-500 blend, sometimes called the "Wolverine stack." She says the peptides are "known for controlling inflammation," "speeding up recovery," and "generating new cell growth." Three days after starting, she noticed improved ankle mobility and less tightness. She plans to keep going until she's fully recovered.
That's a specific, testable set of claims, and she's telling a 31,000-person audience that a peptide stack changed her recovery in 72 hours. That's worth looking at closely, because the gap between animal data and human clinical evidence here is wider than most TikTok threads let on.
Does the science back this up?
Partially, but the human evidence is thin. The preclinical data for BPC-157 is genuinely interesting. The TB-500 story is even less settled in humans. Neither peptide has cleared a Phase III clinical trial for musculoskeletal injury in people.
BPC-157 (body protection compound) has shown real effects on tendon healing in rodent models. Tkalcevic et al. (2007, Journal of Physiology and Pharmacology) found accelerated tendon-to-bone healing in rats given BPC-157. Huang et al. (2015, International Orthopaedics) showed improved Achilles tendon healing in rats. The proposed mechanism involves upregulation of growth hormone receptor expression and nitric oxide signaling, which would plausibly support tissue repair.
TB-500 is a synthetic version of thymosin beta-4, a peptide involved in actin regulation and angiogenesis. Animal studies (Goldstein et al., 2012, Annals of the New York Academy of Sciences) suggest it promotes wound healing and reduces inflammation. But there are no published randomized controlled trials in humans for either peptide used in combination the way Abbey describes.
What did they get wrong (or right)?
Give her credit where it's due: the underlying mechanisms she gestures at are real. BPC-157 and TB-500 do have plausible anti-inflammatory and tissue-regenerative properties in animal research. Calling this combination a recovery tool is not science fiction.
What she gets wrong, or at least glosses over, is attribution. Her recovery at 15 weeks post-Achilles surgery is also exactly when most patients start seeing meaningful functional gains regardless of what they're taking. Physical therapy, time, and surgical success are the dominant variables here. Claiming she "started feeling a difference three days later" could easily be coincidence layered over expected post-surgical progress.
She also frames these peptides as simply "known for" doing things, when most of that reputation is built on rodent data and community anecdote, not controlled human trials. That framing papers over a lot of scientific uncertainty, and her audience deserves to know the difference between animal evidence and clinical proof.
What should you actually know?
BPC-157 and TB-500 are not FDA-approved drugs. They exist in a gray zone: compounded peptides available through some telehealth and research-chemical channels, but without the regulatory review that would confirm safety, purity, or dosing standards in humans. The FDA issued guidance in 2023 restricting certain compounded peptides, and the regulatory status of these specific compounds shifts depending on the supplier and formulation.
The "Wolverine stack" nickname is gym culture branding, not a clinical designation. There are no studies on this specific combination in post-surgical Achilles rupture patients.
If you had Achilles surgery, the evidence-based path forward is structured physical therapy guided by your surgeon's protocol. Peptide therapy sits outside that evidence base right now. Some clinicians are beginning to use these in monitored settings, but anyone injecting these should be doing so under medical supervision with sourcing from a licensed compounding pharmacy, not a gray-market supplier.
The honest summary: the animal science is intriguing, the human evidence doesn't yet support the confidence Abbey's tone implies, and her three-day turnaround story is not proof of anything.